Profile data is unavailable for this security.
About the company
Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
- Revenue in EUR (TTM)5.52bn
- Net income in EUR420.00m
- Incorporated--
- Employees8.70k
- LocationUcb SAAllee de la Recherche, 60ANDERLECHT 1070BelgiumBEL
- Phone+32 25599999
- Fax+32 25599900
- Websitehttps://www.ucb.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Recordati Industria Chimica e Farma SpA | 1.85bn | 312.34m | 8.06bn | 4.30k | 25.68 | 5.12 | 18.40 | 4.35 | 1.50 | 1.50 | 8.90 | 7.52 | 0.5439 | 1.74 | 5.53 | -- | 9.17 | 12.82 | 11.86 | 16.38 | 69.42 | 71.05 | 16.85 | 22.48 | 0.8114 | 15.90 | 0.5261 | 61.84 | 17.29 | 7.55 | -19.08 | 1.58 | 45.87 | 6.23 |
| Ipsen SA | 3.16bn | 593.20m | 8.80bn | 5.74k | 15.59 | 2.60 | 9.42 | 2.79 | 6.74 | 7.32 | 34.75 | 40.45 | 0.5956 | 2.10 | 5.27 | -- | 11.20 | 9.91 | 14.78 | 13.80 | 83.28 | 82.00 | 18.81 | 15.23 | 1.58 | 47.09 | 0.1904 | 21.11 | 5.24 | 9.43 | -8.26 | 17.05 | 0.9854 | 3.71 |
| Qiagen NV | 2.00bn | 394.82m | 9.74bn | 6.18k | 24.74 | 2.99 | 16.53 | 4.87 | 1.72 | 1.72 | 8.68 | 14.20 | 0.3444 | 2.21 | 6.03 | 323,383.80 | 6.81 | 5.04 | 8.51 | 6.02 | 64.65 | 65.39 | 19.76 | 15.54 | 2.09 | 30.33 | 0.3494 | -- | -4.89 | 8.60 | -17.44 | -- | 3.72 | -- |
| Croda International Plc | 2.39bn | 743.60m | 10.28bn | 5.83k | 13.84 | 3.72 | 11.60 | 4.30 | 4.65 | 4.65 | 14.96 | 17.30 | 0.6051 | 2.43 | 5.85 | 358,678.10 | 18.92 | 12.85 | 22.04 | 15.05 | 47.17 | 45.61 | 31.27 | 20.16 | 1.43 | 23.80 | 0.2021 | 48.63 | 10.57 | 8.76 | 102.40 | 23.14 | -0.8817 | 5.41 |
| BioMerieux SA | 3.59bn | 452.40m | 11.51bn | 13.08k | 25.49 | 3.19 | 18.90 | 3.21 | 3.82 | 3.82 | 30.28 | 30.49 | 0.7331 | 2.33 | 5.39 | -- | 9.00 | 9.87 | 11.57 | 13.16 | 55.97 | 55.96 | 12.27 | 12.94 | 1.31 | 266.91 | 0.1218 | 17.01 | 6.31 | 9.42 | -24.74 | 13.70 | 9.33 | 20.11 |
| Eurofins Scientific SE | 6.71bn | 658.20m | 11.69bn | 61.38k | 18.35 | 2.44 | 9.85 | 1.74 | 3.31 | 2.92 | 33.73 | 24.84 | 0.6914 | 34.68 | 4.92 | 109,355.00 | 7.04 | 7.70 | 8.71 | 9.70 | 22.54 | 23.80 | 10.18 | 11.58 | 1.22 | 8.08 | 0.4067 | 19.13 | -0.0834 | 17.70 | -34.73 | 20.14 | 21.85 | 33.03 |
| UCB SA | 5.52bn | 420.00m | 15.09bn | 8.70k | 35.95 | 1.62 | 14.94 | 2.73 | 2.16 | 2.15 | 28.69 | 47.81 | 0.3669 | 1.88 | 4.82 | 633,919.30 | 2.79 | 6.23 | 3.48 | 7.82 | 69.66 | 73.49 | 7.61 | 14.76 | 0.7702 | 9.12 | 0.2424 | 31.62 | -4.50 | 4.02 | -60.19 | -11.00 | 12.16 | 2.42 |
| argenx SE | 383.19m | -661.99m | 18.59bn | 843.00 | -- | 7.07 | -- | 48.51 | -12.22 | -12.22 | 7.09 | 47.39 | 0.1373 | 0.1744 | 2.94 | 454,558.90 | -23.71 | -21.60 | -26.37 | -24.30 | 92.83 | -- | -172.76 | -188.60 | 8.42 | -80.20 | 0.0044 | -- | -17.40 | 58.50 | -73.81 | -- | 204.62 | -- |
| Merck KGaA | 22.23bn | 3.33bn | 21.16bn | 64.23k | 21.43 | 2.79 | 4.12 | 0.9516 | 7.64 | 7.64 | 51.09 | 59.63 | 0.4736 | 2.00 | 5.49 | 346,120.30 | 7.11 | 5.14 | 9.05 | 6.72 | 61.65 | 62.61 | 15.02 | 11.92 | 0.7957 | 26.91 | 0.2856 | 9.64 | 12.93 | 8.90 | 8.87 | 5.47 | 6.62 | 11.97 |
| Genmab A/S | 1.96bn | 741.92m | 22.20bn | 1.66k | 29.91 | 5.97 | -- | 11.32 | 83.72 | 83.72 | 221.20 | 419.77 | 0.5317 | -- | 3.15 | 8,792,169.00 | 20.11 | 19.27 | 21.44 | 20.51 | -- | -- | 37.83 | 40.71 | -- | -- | 0.0213 | -- | 72.07 | 43.90 | 83.58 | 37.99 | 29.07 | -- |
Data as of Mar 21 2023. Currency figures normalised to Ucb SA's reporting currency: Euro EUR
21.06%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Wellington Management Co. LLPas of 30 Dec 2022 | 20.07m | 10.32% |
| Fidelity Management & Research Co. LLCas of 31 Jan 2023 | 4.07m | 2.09% |
| The Vanguard Group, Inc.as of 03 Mar 2023 | 3.39m | 1.74% |
| Norges Bank Investment Managementas of 31 Dec 2022 | 3.01m | 1.55% |
| BlackRock Fund Advisorsas of 01 Mar 2023 | 2.85m | 1.47% |
| Baillie Gifford & Co.as of 16 Mar 2023 | 1.94m | 1.00% |
| Artisan Partners LPas of 31 Dec 2022 | 1.51m | 0.78% |
| BlackRock Advisors (UK) Ltd.as of 02 Mar 2023 | 1.47m | 0.76% |
| Amundi Asset Management SA (Investment Management)as of 14 Mar 2023 | 1.46m | 0.75% |
| Degroof Petercam Asset Management SAas of 30 Nov 2022 | 1.19m | 0.61% |
More ▼
Data from 31 Dec 2022 - 14 Mar 2023Source: FactSet Research Systems Inc.
